Last reviewed · How we verify
FluLaval® TF
At a glance
| Generic name | FluLaval® TF |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of GSK Biologicals' FluLaval® TF (PHASE1)
- Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04 (PHASE3)
- Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluLaval® TF CI brief — competitive landscape report
- FluLaval® TF updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI